Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Abbott: Q3 Earnings Snapshot
On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
Abbott Laboratories Raises Its Outlook on Strong Medical Device Sales
Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices.Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and nutrition divisions.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.
ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Abbott Laboratories (NYSE:ABT) will release earnings results for its third quarter, before the opening bell on Wednesday, Oct ...
Benzinga.com18h
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Abbott Q3: Strong Growth In Medical Device And Pharma
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
The Motley Fool1mon
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...
pharmaphorum2d
A history of Abbott and AbbVie
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...